RxDoctor Payments Data

Mindi Hamby, MD

Family Medicine · Hermitage, TNNPI 1306827605

Payments from drug & device makers

$13,432in general payments, 2019–2025

Across 858 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • GSK$1K
  • AstraZeneca$891
  • Pfizer$685
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$13,367100%
  • Education$650%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,432 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$55,820
Medicare patients
124
Services billed
1,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$54,054
MounjaroTirzepatide32$52,214
XareltoRivaroxaban38$40,326
FarxigaDapagliflozin Propanediol37$36,987
EliquisApixaban25$25,946
JardianceEmpagliflozin15$24,800
Tresiba Flextouch U-200Insulin Degludec16$23,829
Repatha SureclickEvolocumab19$22,815
Xultophy 100-3.6Insulin Degludec/Liraglutide12$21,816
GlyxambiEmpagliflozin/Linagliptin19$12,955
QuliptaAtogepant12$12,898
JanuviaSitagliptin Phosphate12$6,807
Rosuvastatin Calcium234$3,514
PremproEstrogen,con/M-Progest Acet13$3,054
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$1,720$75,87048 claims
Lilly USA, LLCMounjaro$321$52,21432 claims
Johnson & JohnsonXarelto$441$40,32638 claims
Boehringer IngelheimJardiance, Glyxambi$144$37,75534 claims
AstraZenecaFarxiga$891$36,98737 claims
PfizerEliquis, Prempro$685$29,00038 claims
AbbVieQulipta, Synthroid$2,448$15,37641 claims
MerckJanuvia$133$6,80712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →